Author: Lee Kettley

Evaluation and Management of Metastatic Lung Cancer

For demo purposes only – Not for redistribution Evaluation and Management of Metastatic Lung Cancer In this course we will learn about the basic principles of diagnosing, staging, and treating metastatic non-small-cell lung cancer. Through patient cases and expert discussions, we walk you evaluation, including biomarker testing, treatment selection and follow up for these patients.…

Read the full article

Management of Non-muscle Invasive Bladder Cancer (ASCO Tumor Board)

For demo purposes only – Not for redistribution Management of Non-muscle Invasive Bladder Cancer In this tumor board, experts explore multidisciplinary treatment approaches for a 73-year-old woman with grade 3, pT1 transitional cell carcinoma. The cancer recurred upon initial treatment. Research evidence, as well as patient and tumor-related factors that impact treatment selection are discussed…

Read the full article

ESMO Video Collection Example With Access Codes

This is for demonstration purposes only. Not for general distribution. × Dismiss alert LBA37 – A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung) Video Slides Video Slides Download Slides Proffered Paper Session © Copyright 2022 European Society for Medical Oncology (ESMO).…

Read the full article

ASCO Expert Answers – First-line Immunotherapy for Metastatic Gastroesophageal Cancers

Return For demo purposes only – Not for redistribution First-line Immunotherapy for Metastatic Gastroesophageal Cancers Using a case-based approach, this course explores recent research findings on immunotherapy for metastatic gastroesophageal cancer. This course includes a special focus on biomarker testing integration into the treatment of gastroesophageal cancers. View full screen Learning Objectives Upon participation in…

Read the full article

ASCO Expert Answers – Second-line Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Return For demo purposes only – Not for redistribution Second-line Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma Only 35% of patients with relapsed/refractory DLBCL receive additional therapy, despite availability of multiple second-line regimens that can produce prolonged remissions. In this course, Dr. Loretta Nastoupil of MD Anderson Cancer will use patient cases to explore who…

Read the full article

ASCO Expert Answers

ASCO® Expert Answers For demo purposes only – Not for redistribution Second-line Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma Launch Course First-line Immunotherapy for Metastatic Gastroesophageal Cancers Launch Course

CMP22UN009731

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER Jhund, PS, Kondo, T, Butt, JH, et al. Nat Med. 2022;28(9):1956-1964. Article Access Article Bibliography Download PDF Prescribing information DOWNLOAD PDF Site provided by Springer Healthcare. Part of the Springer Nature Group. Privacy policy Terms…

Read the full article

ePrint Collection

Article 1 – Lorem ipsum dolor sit amet consectetur adipiscing elit Author(s): Jane Doe et al. Copyright: © Springer Healthcare Published: Month Day, Year Access Article Article 2 – Lorem ipsum dolor sit amet consectetur adipiscing elit Author(s): Jane Doe et al. Copyright: © Springer Healthcare Published: Month Day, Year Access Article Article 3 –…

Read the full article

European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis

Eller, K et al. Nephrol Dial Transplant. 2022 Jun 23;37(7):1229-1234. doi: 10.1093/ndt/gfac034. This article was published on February 23, 2022, at academic.oup.com. Access Article Site provided by Springer Healthcare. Part of the Springer Nature Group. Privacy Policy